Kornimate/medical-research-clean huggingface dataset:
the effects of rifaximin therapy in irritable bowel syndrome

Conditions: IBS

Summary: to evaluate the efficacy of rifaximin therapy started prior to completion of advanced examination procedure (before colonoscopy) of patients pre-diagnosed with irritable bowel syndrome, and implement it into clinical practice.

irritable bowel syndrome(ibs) is a chronic relapsing disorder with unknown etiology characterized by abdominal pain and bowel habit changes without an organic pathology. pathophysiology is not fully understood, bacterial overgrowth is one of the reasons. because of that, use of drugs effective on the gut flora has been raised; rifaximin is one of them. this study investigated the effectiveness of rifaximin on ibs. this randomized, double-blinded, controlled study began with 500 patients(144 of them removed because of incompliance). patients those without organic bowel pathology and whom meet the rome-iii criteria, aged between 19-50 yo were enrolled in the study. patients with known rifaximin allergy, lactose intolerance, and those having treated for ibs whit in last 1 month as well as those with alarm symptoms (melena, fever, weight loss, anemia, rectal bleeding) were excluded. after routine biochemistry, blood count, and stool tests, rifaximin tablet was given to a group as 1200 mg. daily in 3 divided doses, placebo tablet was given to another group in same doses for 10 days. improvement in symptoms were scored and recorded on 10.day, 3. and 6.week. in addition to descriptive statistical methods(mean±sd), student's-t and mann-whitney u-tests were used for comparison of quantitative data, chi-square and mcnemar tests were used for comparison of qualitative data. significance was accepted if p \<0.05.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 50 years without alarm symptoms, who were examined at the gastroenterology clinic, without endoscopic assessment, due to complaints of irritable bowel syndrome, and pre-diagnosed with irritable bowel syndrome according to the rome iii criteria, will be included in the study. exclusion criteria: 1. are under the age of 18 years, 2. are allergic to rifaximin, 3. are pregnant and lactating, 4. have documented diseases of the gastrointestinal system (such as gastric and duodenal ulcers, gastric cancer, small intestine and colon cancer, inflammatory bowel disease \[crohn's and ulcerative colitis\], gastroparesis, chronic intestinal ischemia, etc.), 5. have (describe) documented diseases of the pancreas, biliary tract, and liver (such as pancreatitis, biliary colic pain associated with gallstones, acute cholecystitis, choledochal stone, hepatitis, hepatobiliary cancers, etc.), 6. have previously undergone major abdominal surgery, 7. have a systemic disease (such as collagen tissue disorders, kidney dysfunction, systemic infection, etc.), 8. have an identified psychiatric disorder, and/or 9. consume alcohol excessively

Keywords: ibs rifaximin
a study of safety and effectiveness of ultracet in patients with chronic cancer pain

Conditions: Cancer

Summary: the purpose of this study is to evaluate the analgesic (painkiller) effectiveness and safety of combination of tramadol hci (37.5 mg)/acetaminophen (325 mg) in the treatment of chronic cancer pain.

this is an open-label (all people know the identity of the intervention) study. a total of 35 participants will be enrolled in this study. participants will receive tablet of combination of tramadol hci (37.5 mg)/acetaminophen (325 mg) on day 1. participants may increase their daily dosage of study medication as 1 to 2 tablets every 4 to 6 hours as needed for pain relief, up to maximum of 8 tablets per day. rescue medication consisting of extra strength tylenol (500 mg) 2 tablets daily for the first six days of the open-label phase will be allowed so that the total daily dose of acetaminophen will not exceed 4,000 mg. the total duration of the study treatment for each participant will be approximately 6 weeks. safety will be evaluated by assessment of adverse events, clinical laboratory tests, skin site assessments, vital signs, and physical examination which will be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participants whose pain has reached a stage now requiring treatment with a weak opioid, according to the opinion of treating physician * participants who have received a regular weak opioid, for at least 48 hours and at a dosage appropriate for their pain at that time * participants with a histologically, radiologically or hematologically confirmed malignancy; whose pain is judged by the investigator to be caused by the malignancy exclusion criteria: * participants who have already received regular treatment with a strong opioid for their cancer pain. this should not exceed more than 3 doses of a strong immediate release opiod in last 7 days, and none in last 24 hours * participants with significant abnormalities in hepatic or renal function which would in the opinion of the investigator, prevent the participants involvement in the study * participants with a history of allergy or hypersensitivity to tramadol or acetaminophen * participants who, at entry have treatments planned which may alter abruptly, the degree or nature of pain experienced (eg radiotherapy, neurological techniques surgery) * participants with a history of abuse of opioid analgesics prior to their diagnosis of cancer

Keywords: cancer chronic cancer pain tramadol hci acetaminophen analgesics pain assessment
trends of acute intoxication in poison control centre

Conditions: Poison Drug; Poison;Medicinal;Wrong Drug; Poisoning

Summary: the study aim to investigate the trend of poisoning and its causative agents among different egyption people ages between 2015 and 2019

this study aim to report different types of intoxication, the significant ages that intend to accidently ingest poisons or commit suicide, and the most commonly used chemicals in toxication, showing different rautes of administration between the years 2015 and 2019

Eligibility criteria:
inclusion criteria: - all medical records for patients admitted to pcc-asuh emergency departmentwith the diagnosis of acute intoxication from 2015 t0 2019 exclusion criteria: - any cases of acute intoxication before 2015 or after the end of 2019 cases of chronic intoxications were excluded

Keywords: food poisoning insecticides detergents heavy metals
efficacy and safety of dkb-119 in patients in crow's feet

Conditions: Crow's Feet

Summary: to prove the non-inferiority of dkb-119 by evaluating the injecting efficacy and safety dkb-119 and control for patients in crow's feet

a single center, randomized, subject and evaluator blinded, split-face, pivotal clinical trial

Eligibility criteria:
inclusion criteria: * those who are over 19 under 70 ages. * those who score 2 or more in the lcl severity evaluation. * those who have visually symmetrical crow's feet on both sides. * etc. exclusion criteria: * pregnancy and lactating women. * etc.
online insomnia intervention to reduce alcohol use

Conditions: Alcohol Use Disorder; Heavy Drinking

Summary: alcohol use disorder (aud) inflicts enormous physical, emotional, and financial burdens on the individual and society at large. insomnia is highly prevalent among individuals with aud, and disrupted sleep contributes substantially to alcohol-related problems. while research suggests that treating insomnia may effectively reduce aud, the degree to which treating insomnia in heavy drinkers reduces alcohol consumption and prevents the onset of severe aud is not known. this study will be the first to evaluate an internet-based version of cognitive behavioral therapy for insomnia (cbt-i) in community-dwelling, heavy drinking adults with insomnia. sleep healthy using the internet (shuti), the most widely-used and well-validated version of internet-based cbt-i will be used. the primary aim is to reduce alcohol consumption and insomnia severity in this population.

the study will investigate the efficacy of sleep healthy using the internet (shuti), an online insomnia intervention, in reducing alcohol consumption and improving sleep in heavy drinkers with insomnia. the participants are ages 18-50 (n=100) who have insomnia and are heavy drinkers (at least weekly binge drinking episodes \[4/5+ drinks in one sitting for men/women\]). this intervention has a mixed methods randomized controlled trial design. participants will be randomly assigned to either the online shuti intervention (n=50), or a patient education (pe) website (n=50). quantitative data will be collected via online redcap surveys and daily online diaries. qualitative data will be collected via semi-structured telephone interviews. data collection points will be pre-intervention, post-intervention, and 3- and 6-months postintervention.

Eligibility criteria:
inclusion criteria: * 18-50 years old * fluency in english * at least weekly binge drinking episodes (4/5+ drinks for women/men)\] * insomnia severity index (isi) scores #15 exclusion criteria: * no internet access * past or current substance use disorder (other than mild or moderate aud) * obstructive sleep apnea * bipolar disorder, schizophrenia, or other psychotic spectrum disorder * pregnancy or nursing for women * any serious medical or neurological problems

Keywords: sleep cognitive behavioral therapy cbt alcohol app non pharmacological
covid-19 immunogenicity of a third dose of mrna-1273 vaccine among cancer patients

Conditions: Covid19; SARS-CoV2 Infection

Summary: investigators will evaluate the immunogenicity of a third dose of mrna-1273 sars-cov-2 vaccine among cancer patients receiving the recommended third vaccine dose


Eligibility criteria:
inclusion criteria: * at least 18 years of age * is a cancer patient enrolled in the cancer patient immune response to covid-19 vaccine study (a basic science study) mcc 21138 or who has completed the two mrna-1273 vaccine series prior to march 31, 2021. * understands, agrees and is able to comply with the study procedures and provides written informed consent. * has no known or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reactions to the vaccine or its excipients. * has not received more or less than 2 doses of mrna-1273 vaccine exclusion criteria: * participants who will not return for the third vaccine dose

Keywords: immunogenicity antibodies vaccine adverse events
a study of pegasys (peginterferon alfa-2a (40kd)) plus copegus (ribavirin) in patients with chronic hepatitis c (chc) genotype 1 and human immunodeficiency virus-1 (hiv-1) co-infection

Conditions: Hepatitis C, Chronic

Summary: this 2-arm study will compare the efficacy and safety of treatment with pegasys (180 µg weekly) plus copegus (800 mg daily) and pegasys (180 µg weekly) plus copegus (1000-1200 mg daily) in interferon-naive patients with chc genotype 1 co-infected with hiv-1. treatment will be administered for 48 weeks, and this will be followed by 24 treatment-free weeks. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, ≥18 years of age * chc genotype 1 * stable hiv-1 infection exclusion criteria: * previous treatment with an alpha interferon, ribavirin, viramidine, levovirin, amantadine or investigational hcv protease or polymerase inhibitors * medical condition associated with liver disease other than chc infection
a phase ii study of ak104 combination with lenvatinib versus lenvatinib for second-line hcc

Conditions: HCC; Hepatocellular Carcinoma

Summary: this is a phase ii, randomized, open-label, global, multi-center study to compare the efficacy and safety of ak104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.


Eligibility criteria:
inclusion criteria: 1. signed the informed consent form (icf) voluntarily. 2. age ≥18 years at time of signing icf. 3. histologic or cytologic confirmation of hcc, or clinical diagnosis of hcc as per aasld criteria. 4. bclc stage b or c, and not suitable for curative surgical or local therapy. 5. participants have progressed on the prior first-line systemic treatment with atezolizumab plus bevacizumab combination treatment. 6. at least one measurable lesion according to recist v1.1. 7. child-pugh class a . 8. ecog performance status of 0 or 1. 9. with a life expectancy of ≥3 months. 10. adequate organ and hematologic function. exclusion criteria: 1. known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc. 2. tumor thrombus invasion of superior mesenteric vein. 3. has a known history of, or any evidence of cns metastases. 4. has received anti-cancer therapy for hcc within 3 weeks prior to the first dose of study treatment. 5. has received systemic anti-cancer therapy other than atezolizumab and bevacizumab. 6. has participated in another clinical study within 4 weeks prior to the first dose. 7. history of liver transplantation. 8. history of hepatic encephalopathy. 9. clinically symptomatic or recurrently drained pleural effusion, pericardial effusion, or ascites. 10. history of bleeding event due to esophageal and/or gastric varices within 6 months prior to the first dose of study treatment.
treatment of naevus flammeus using intense pulsed light and pulsed dye laser

Conditions: Port-Wine Stain

Summary: the purpose of the trial is to compare efficacy and adverse effects of pulsed dye laser and intense pulsed light in patients with port wine stains.


Eligibility criteria:
inclusion criteria: * patients with previously untreated and previously laser-treated naevus flammeus. naevus flammeus measuring at least 5 x 7 cm within a single anatomical area. for example, the face corresponding to dermatomes v1, v2 and v3, back, abdomen, arms and legs.patients aged two or above.patients with skin types i-iii. exclusion criteria: * patients below two years of age. * pregnant or breastfeeding patients. * patients with known increased sensitivity to visible light. * patients with a tendency to produce hypertrophic scars or celoids. * patients with skin types iv, v and vi. * patients who are clearly pigmented following recent exposure to the sun or a solarium. * patients treated with roaccutane during the last six months. * patients who are not considered able to follow the treatment protocol (e.g. severely alcoholic patients, dementia patients, mentally ill patients, etc.).

Keywords: port wine stains naevus flammeus
postoperative intraperitoneal pain management following laparoscopic cholecystectomy

Conditions: Post Operative Pain

Summary: postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. no. study has investigated ip granisetron as an adjuvant to standard care for postoperative pain management in patients undergoing lc.

postoperative pain is a main challenge for delayed hospital discharge in laparoscopic cholecystectomy. . postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. granisetron is frequently used as a premedication to avoid postoperative nausea and vomiting in patients who have undergone general anesthesia. the purpose of this study is evaluating the efficacy and tolerability of ip granisetron on postoperative pain control in patients undergoing lc

Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo elective lc. * adults (males and/or females) between the ages of 18-70 years old. exclusion criteria: * chronic pain other than cholelithiasis. * patients who received analgesics or sedatives 24 h before scheduled surgery. * severe hepatic (child pugh class b and c) and renal dysfunction (crcl \<30ml/min) * previous allergic response to granisetron. * pregnancy and lactation * patients with communication problems, cognitive dysfunction, or psychological disorders * daily corticosteroid use

Keywords: laparoscopic post-operative pain serotonin 5ht3 receptor antagonist
stem cells for the improvement of erectile and cardiac function in aging men

Conditions: Erectile Dysfunction; Cardiac Disease

Summary: men who present with erectile dysfunction as defined as an iief (international index of erectile function) score less than 21 will be evaluated for risk factors for cardiovascular disease (cvd). this is a single-blind study. subjects will be randomized in a 2:1 fashion for treatment (arm 1) versus placebo (arm 2). adipose tissue (fat) will be harvested from all patients and stem cells will be cultured. for those patients in the placebo arm the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.

baseline assessment of patients will include completion of 6 questionnaires, ekg (electrocardiogram), vision testing using a standard eye chart, markers of endothelial dysfunction hormone evaluation, laboratory blood tests, vital signs, penile ultrasound (optional), echocardiogram, chest x-ray, and endothelial function assessment (endopat). the adipose tissue sample is sent to celltex's state-of-the-art laboratory in houston, texas. for those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm. the subject (patient) will receive an infusion of either autologous stem cells (cells made from his own fat tissue) or placebo every 2 weeks for 3 months. placebo will be in the form of normal saline. subjects will be closely monitored every two weeks for first 3 months and once the treatment is complete, subjects will be monitored every 3 months for the first year. each of the previously mentioned tests will be performed at the 3, 6, 9, and 12 month mark. however, the penile ultrasound (optional) and the echocardiogram will be performed only at the 3 and 12 month mark.

Eligibility criteria:
inclusion criteria: * men 40 years of age or older * men with erectile dysfunction as defined by iief score less than 21 * men with endothelial dysfunction as defined as an rhi score less than 2 * men with normal testosterone levels (300 ng/dl) exclusion criteria: * men under the age of 40 * men with normal erectile function * men with normal endothelial function * men with low testosterone levels (less than 300ng/dl)

Keywords: stem cells cardiovascular disease erectile dysfunction
cancer and disorders of cognitive functions and quality of life: "cognitive rehabilitation in patients suffering from cancer and treated with chemotherapy"

Conditions: Cancer

Summary: our study aims to measure the impact of cognitive rehabilitation workshops on the development of cognitive functions and quality of life of patients expressing a cognitive complaint

the main objective of our study was to evaluate, in patients treated for cancer expressing the cognitive complaint during or after treatment, interest workshops on improving cognitive rehabilitation felt their cognitive functions and their quality of life. the primary endpoint was the proportion of patients showing an improvement in the score of perceived deficiencies (score ranging from 0 to 72) of the fact-cog after treatment. the fact-cog is a self-administered questionnaire assessing the patients felt their cognitive difficulties (memory, attention, concentration) and the impact of these difficulties on their quality of life. the improvement is defined as an increase of 7 points \>= cognitive score won by the (a) patient (e) after the treatment

Eligibility criteria:
inclusion criteria: * patients older than 18 years * solid tumor or haematological * chemotherapy and / or targeted therapy in the adjuvant or metastatic * sequential processing * subjective cognitive complaints during or after treatment assessed by four items of the fact-cog (impact on quality of life). score ≥ 4/16 questions q35, q37, q38 and q41 fact cog - patient in remission or pause therapeutic * subjective between 1 month and 5 years after the end of chemotherapy and / or targeted therapy cognitive complaints (ongoing treatment with herceptin is not a non-inclusion criteria) * lack of personality disorders and / or psychiatric disorder scalable * no known brain metastases * lack of primary brain tumor * lack of analgesic treatment with opioids or class 3 * having signed informed consent to participate in the study * mastery of the french language exclusion criteria: * primary cancer of the central nervous system or brain metastases * pathology malignant hematologic * disorders of higher functions documented * pathology psychiatric scalable * use documented drug * cancer treated in childhood * patient or opioids analgesics in class 3 * consumption of alcohol * patient unable to respond to cognitive tests and cognitive rehabilitation * refusal to participate

Keywords: cognitive functions quality of life cancer
implantation of an advanced practice nurse in the complex care pathway of patients with aml

Conditions: Myeloid Leukemia

Summary: advanced practice nurse (apn) is a new contributor in the french healthcare system. apn is part of a multidisciplinary team and aim to monitor patients under the coordination of the doctor particularly in onco-hematology. the aim of the study is to describe the different perceptions and expectations of apn monitoring according to patients with acute myeloid leukemia (aml) and their care team. this study will involve 10 patients, recruited over a provisional period of 5 months and 25 member of care team. patients and their care team will be asked about their perceptions and expectations of apn participation in (aml monitoring) during a semi-structured interviews.


Eligibility criteria:
inclusion criteria: * patient with aml * treated with a new targeted oral therapy as monotherapy or in combination: * venetoclax\* in combination with ivosidenib (idh1 inhibitor) * onureg\* (azacitin: pyrimidine analogue) * venetoclax (bcl-2 protein inhibitor) in combination with subcutaneous azacitin * whose follow-up is provided alternately by a hematologist and an ipa. * affiliated to a social security scheme exclusion criteria: * moderate or severe cognitive impairment * language barrier * other communication disorders

Keywords: advanced practice nurse acute myeloid leukemia,